Patents by Inventor Yimin Qian

Yimin Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12264157
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: April 1, 2025
    Assignees: Arvinas Operations, Inc., Yale University
    Inventors: Andrew P. Crew, Craig M. Crews, Xin Chen, Hanqing Dong, Caterina Ferraro, Yimin Qian, Kam Siu, Jing Wang, Meizhong Jin, Michael Berlin, Kurt Zimmermann, Lawrence Snyder
  • Publication number: 20250092039
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Application
    Filed: October 18, 2024
    Publication date: March 20, 2025
    Inventors: Robert LUO, Ji LIU, Pin HUANG, Jie SU, Yan FENG, Ke LIU, Jie FAN, Wei HE, Yimin QIAN
  • Publication number: 20250084095
    Abstract: The present disclosure relates to novel CDK inhibitors, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions associated with CDK.
    Type: Application
    Filed: July 22, 2024
    Publication date: March 13, 2025
    Inventors: Xiangzhu WANG, Yimin QIAN, Wei HE, Jie SU, Ke LIU, Jie FAN
  • Publication number: 20250080594
    Abstract: The present application discloses a method and an apparatus for a media stream transmission based on an edge device, and an electronic device. The method includes: an edge all-in-one machine located in a second network receives a live streaming request message from a station device management cloud module in a first network, generates media stream service information based on an identifier of a camera module, and sends the media stream service information to the station device management cloud module to cause the station device management cloud module to request a media stream from a target network video recorder. The edge all-in-one machine further receives the media stream recorded by the target network video recorder through the camera module, and transmits the media stream to a client based on the edge live streaming address.
    Type: Application
    Filed: August 29, 2024
    Publication date: March 6, 2025
    Inventors: Yimin Li, Zhenxing Qian, Xuebo Hong, Dong Chen, Lixin Guan
  • Publication number: 20250077199
    Abstract: The present disclosure provides a device driving method, apparatus, and electronic device. The method comprises: receiving call parameters comprising a device identification, a device class, and a driving instruction of a target device; looking up a target function-class module matching the device class in at least one function-class module according to the device class and a pre-set first mapping relationship; looking up, by using the target function-class module, a target function sub-module in at least one function sub-module according to the device identification and a second mapping relationship; sending the driving instruction to the target device via the target function sub-module, to drive the target device to execute a task corresponding to the driving instruction.
    Type: Application
    Filed: August 29, 2024
    Publication date: March 6, 2025
    Inventors: Xuebo Hong, Zhenxing Qian, Yimin Li, Dong Chen, Lixin Guan
  • Patent number: 12239711
    Abstract: The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: March 4, 2025
    Assignee: Arvinas Operations, Inc.
    Inventors: Andrew P. Crew, Craig M. Crews, Hanqing Dong, Keith R. Hornberger, Yimin Qian, Lawrence B. Snyder, Jing Wang
  • Publication number: 20250063098
    Abstract: Embodiments of the disclosure discloses a service management system, a service management method, a device and a storage medium. The system includes a server, a plurality of devices, and a plurality of clients establishing a communication connection with the plurality of devices; the server is configured to receive a service execution request, determine a target client from the plurality of clients based on an identifier of a target client comprised in the service execution request, and forward the service execution request to the target client; and the target client is configured to parse service information comprised in the service execution request, determine a target device corresponding to the service information from the plurality of devices, generate a driving instruction for the target device by invoking a target device driving service of the target device, and drive the target device with the driving instruction to respond to the service information.
    Type: Application
    Filed: August 16, 2024
    Publication date: February 20, 2025
    Inventors: Zhenxing QIAN, Yimin LI, Xuebo HONG, Lixin GUAN, Dong CHEN
  • Patent number: 12208095
    Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2? breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: January 28, 2025
    Assignee: Arvinas Operations, Inc.
    Inventors: Andrew P. Crew, John Flanagan, Sheryl Maxine Gough, Royal J. Haskell, III, Marcia Dougan Moore, Yimin Qian, Ian Charles Anthony Taylor, Jing Wang
  • Patent number: 12211126
    Abstract: The application relates to a run-length stripping method for generating skeleton lines of complex plain river networks, including following steps: 1. constructing an empty raster field, each raster row generates an empty run-length linked list; 2. completing raster compression on each row, and compressing the continuous grids into run-length units and inserting them into the raster row run-length linked list; 3. establishing a raster field river boundary grid search template; 4. setting two discriminant functions to judge whether a grid on a raster field is a redundant grid; 5. searching all boundary grids along a raster field boundary, and marking and stripping all redundant grids based on two discriminant functions respectively; 6. analyzing whether the boundary grid is stripped, if so, returning to continue stripping, otherwise, entering the next step; 7. converting the non-stripped grid into skeleton line data in vector form.
    Type: Grant
    Filed: April 18, 2024
    Date of Patent: January 28, 2025
    Assignee: Zhejiang Institute of Hydraulics & Estuary (Zhejiang Institute of Marine Planning and Design)
    Inventors: Jinhua Wen, Caijie Yang, Helong Wang, Yimin Qian, Longqiang Su, Qifeng Li, Caiming Chen, Chenkai Cai
  • Patent number: 12195459
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: January 14, 2025
    Assignee: Tiger Biotherapeutics Inc.
    Inventors: Robert Luo, Ji Liu, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Publication number: 20250002473
    Abstract: The present disclosure relates to at least one entity chosen from a compound of Formula (I), tautomers, stereoisomers or a mixture of stereoisomers, hydrates, and deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and their use as epidermal growth factor receptor (EGFR) degraders for the prevention and treatment of diseases and conditions, e.g., cancer. The present disclosure also relates to pharmaceutical compositions containing such entities, and their use in treating or preventing a disease or disorder associated with EGFR.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 2, 2025
    Applicant: Accutar Biotechnology Inc.
    Inventors: Ji LIU, Pin HUANG, Ke LIU, Wei HE, Yimin QIAN, Jie FAN, Robert Luo
  • Publication number: 20240425519
    Abstract: Spirocyclic compounds that are KLHDC2 ligands and methods for inhibiting the enzymatic activity of KLHDC2 using the ligands.
    Type: Application
    Filed: October 31, 2022
    Publication date: December 26, 2024
    Applicants: University of Washington, ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Ning ZHENG, Domnita Valeria RUSNAC, Jie FAN, Yimin QIAN, Ke LIU
  • Patent number: 12172981
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: December 24, 2024
    Assignee: Arvinas Operations, Inc.
    Inventors: Andrew P. Crew, Hanqing Dong, Keith R. Hornberger, Yimin Qian, Jing Wang
  • Patent number: 12171831
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: December 24, 2024
    Assignees: Arvinas Operations, Inc., YALE UNIVERSITY
    Inventors: Yimin Qian, Hanqing Dong, Jing Wang, Michael Berlin, Andrew P. Crew, Craig M. Crews
  • Patent number: 12168058
    Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: December 17, 2024
    Assignee: Tiger Biotherapeutics, Inc.
    Inventors: Ji Liu, Robert Luo, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Publication number: 20240398805
    Abstract: The disclosure provides quinazoline based compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.
    Type: Application
    Filed: February 4, 2022
    Publication date: December 5, 2024
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin Qian, Wei HE, Robert LUO, Jie Fan
  • Publication number: 20240382599
    Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.
    Type: Application
    Filed: April 1, 2024
    Publication date: November 21, 2024
    Inventors: Andrew P. Crew, Kurt Zimmermann, Jing Wang, Michael Berlin, Hanqing Dong, Alexey Ishchenko, Yimin Qian, Saul Jaime-Figueroa, George Burslem, Craig M. Crews
  • Publication number: 20240355015
    Abstract: The application relates to a run-length stripping method for generating skeleton lines of complex plain river networks, including following steps: 1. constructing an empty raster field, each raster row generates an empty run-length linked list; 2. completing raster compression on each row, and compressing the continuous grids into run-length units and inserting them into the raster row run-length linked list; 3. establishing a raster field river boundary grid search template; 4. setting two discriminant functions to judge whether a grid on a raster field is a redundant grid; 5. searching all boundary grids along a raster field boundary, and marking and stripping all redundant grids based on two discriminant functions respectively; 6. analyzing whether the boundary grid is stripped, if so, returning to continue stripping, otherwise, entering the next step; 7. converting the non-stripped grid into skeleton line data in vector form.
    Type: Application
    Filed: April 18, 2024
    Publication date: October 24, 2024
    Inventors: Jinhua WEN, Caijie YANG, Helong WANG, Yimin QIAN, Longqiang SU, Qifeng LI, Caiming CHEN, Chenkai CAI
  • Patent number: 12110291
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: October 8, 2024
    Assignee: Tiger Biotherapeutics Inc.
    Inventors: Robert Luo, Ji Liu, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Publication number: 20240317777
    Abstract: The present disclosure relates to a compound of Formula (I), a tautomer, a stereoisomer or a mixture of stereoisomers, a pharmaceutically acceptable salt, a hydrate, or a deuterated derivative thereof and their use in, e.g., treating a disease or disorder associated with CDK2. The present disclosure also relates to pharmaceutical compositions containing such compounds, and their use in treating or preventing a disease or disorder associated with CDK2.
    Type: Application
    Filed: February 23, 2024
    Publication date: September 26, 2024
    Applicant: Accutar Biotechnology Inc.
    Inventors: Xiangzhu Wang, Jie SU, Ke LIU, Wei HE, Jie FAN, Yimin QIAN